Abstract
This perspective examines the report by Zhang and colleagues in this issue of the journal (beginning on page 1081) on the validation and refinement of a set of risk markers for oral premalignant lesion progression that incorporates loss of heterozygosity markers. The perspective also discusses some of the challenges and opportunities of incorporating predictive biomarkers into monitoring and refined enrollment criteria for prevention studies.